Retail Investors Among Getein Biotech, Inc's (SHSE:603387) Largest Stockholders and Were Hit After Last Week's 8.1% Price Drop
Retail Investors Among Getein Biotech, Inc's (SHSE:603387) Largest Stockholders and Were Hit After Last Week's 8.1% Price Drop
Key Insights
关键见解
- Getein Biotech's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public
- 50% of the business is held by the top 25 shareholders
- Insider ownership in Getein Biotech is 41%
- Getein Biotech拥有大量散户投资者的所有权,这表明关键决策受到广大公众股东的影响
- 50% 的业务由前 25 名股东持有
- Getein Biotech的内部所有权为41%
A look at the shareholders of Getein Biotech, Inc (SHSE:603387) can tell us which group is most powerful. We can see that retail investors own the lion's share in the company with 50% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
看看Getein Biotech, Inc (SHSE: 603387) 的股东可以告诉我们哪个集团最强大。我们可以看到,散户投资者拥有该公司的大部分股份,所有权为50%。换句话说,该集团将从对公司的投资中获得最多(或损失最大)。
While insiders who own 41% came under pressure after market cap dropped to CN¥4.7b last week,retail investors took the most losses.
尽管上周市值跌至47亿元人民币后,持有41%的内部人士承受了压力,但散户投资者遭受的损失最大。
Let's take a closer look to see what the different types of shareholders can tell us about Getein Biotech.
让我们仔细看看不同类型的股东能告诉我们关于Getein Biotech的哪些信息。
Check out our latest analysis for Getein Biotech
查看我们对 Getein Biotech 的最新分析
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240125/0-2bdcf8a5aba3bfae3f32a088645fa6a2-0-e5487c07aab084487def93f0ed6ddc3d.png/big)
What Does The Institutional Ownership Tell Us About Getein Biotech?
关于Getein Biotech,机构所有权告诉我们什么?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
机构投资者通常将自己的回报与常见指数的回报进行比较。因此,他们通常会考虑收购相关基准指数中包含的大型公司。
Institutions have a very small stake in Getein Biotech. That indicates that the company is on the radar of some funds, but it isn't particularly popular with professional investors at the moment. So if the company itself can improve over time, we may well see more institutional buyers in the future. We sometimes see a rising share price when a few big institutions want to buy a certain stock at the same time. The history of earnings and revenue, which you can see below, could be helpful in considering if more institutional investors will want the stock. Of course, there are plenty of other factors to consider, too.
各机构在Getein Biotech中所持的股份很小。这表明该公司受到一些基金的关注,但目前在专业投资者中并不特别受欢迎。因此,如果公司本身能够随着时间的推移而有所改善,那么将来我们很可能会看到更多的机构买家。当一些大型机构想同时购买某只股票时,我们有时会看到股价上涨。你可以在下面看到的收益和收入的历史可能有助于考虑是否会有更多的机构投资者想要这只股票。当然,还有很多其他因素需要考虑。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240125/0-2bdcf8a5aba3bfae3f32a088645fa6a2-1-219b848289712f5f3966080238bbfb65.png/big)
Hedge funds don't have many shares in Getein Biotech. En Ben Su is currently the company's largest shareholder with 40% of shares outstanding. Nanjing Aiji Business Information Consulting Co., Ltd. is the second largest shareholder owning 3.5% of common stock, and Aeon Life Insurance Co. Ltd., Asset Management Arm holds about 1.4% of the company stock.
对冲基金在Getein Biotech中持有的股票不多。En Ben Su目前是该公司的最大股东,已发行股份的40%。南京艾吉商业信息咨询有限公司是第二大股东,拥有3.5%的普通股,永旺人寿保险有限公司Ltd.,资产管理部门持有公司约1.4%的股份。
Our studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder.
我们的研究表明,前25名股东共同控制的公司股份不到一半,这意味着该公司的股票分布广泛,没有占主导地位的股东。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.
研究机构所有权是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪也可以达到同样的目的。据我们所知,没有分析师对该公司进行报道,因此它可能处于雷达之下。
Insider Ownership Of Getein Biotech
Getein Biotech的内部所有权
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间确实有所不同。我们的数据反映了个人内部人士,至少涵盖了董事会成员。公司管理层对董事会负责,后者应代表股东的利益。值得注意的是,有时高层管理人员自己也是董事会成员。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常认为内部所有权是一件好事。但是,在某些情况下,这使其他股东更难追究董事会对决策的责任。
Our information suggests that insiders maintain a significant holding in Getein Biotech, Inc. Insiders have a CN¥2.0b stake in this CN¥4.7b business. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.
我们的信息表明,内部人士持有Getein Biotech, Inc.的大量股份。内部人士在这项47亿元的业务中持有20亿元人民币的股份。这可能表明创始人仍然拥有大量股份。你可以点击这里查看他们是否在买入或卖出。
General Public Ownership
一般公有制
The general public, who are usually individual investors, hold a substantial 50% stake in Getein Biotech, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.
公众通常是个人投资者,持有Getein Biotech50%的大量股份,这表明它是一只相当受欢迎的股票。这种所有权规模赋予了公众投资者一定的集体权力。他们可以而且可能确实会影响有关高管薪酬、股息政策和拟议业务收购的决策。
Private Company Ownership
私人公司所有权
Our data indicates that Private Companies hold 3.5%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
我们的数据表明,私人公司持有公司3.5%的股份。仅凭这一事实很难得出任何结论,因此值得研究谁拥有这些私营公司。有时,内部人士或其他关联方通过独立的私人公司持有上市公司的股份权益。
Next Steps:
后续步骤:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 3 warning signs for Getein Biotech you should be aware of.
尽管值得考虑拥有公司的不同群体,但还有其他因素更为重要。一个很好的例子:我们已经发现了你应该注意的Getein Biotech的3个警告信号。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,来看看这份有趣的公司的免费清单吧。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。